Chen X, Hou X, Gao J, et al. Diabetes Obes Metab. 2024 Mar;26(3):878-890. Epub 2023 Nov 30. PMID: 38031821.
Articles Making Use of Data Shared Through the YODA Project
Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine
Venkatasubramaniam A, Mateen BA, Shields BM, et al. BMC Med Inform Decis Mak. 2023 Jun 16;23(1):110. PMID: 37328784; PMCID: PMC10276367.
Assessing the representativeness of trials of Sodium-glucose Cotransporter-2 inhibitors in type 2 diabetes: a comparison of individual-level trial data and people newly prescribed treatment in a Welsh routine care database
Hanlon P, Wightman H, Sullivan M, et al. BMC Med. 2025 Nov 26;23(1):661. PMID: 41299446; PMCID: PMC12659586.
Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials
Naudet F, Pellen C, Fodor LA, et al. BMC Med. 2025 Nov 28. Epub ahead of print. PMID: 41310599.
Evaluating re-identification risks scores in publicly available clinical trial datasets: Insights and implications
Rodriguez A, Williams LJ, Lewis SC, et al. Clin Trials. 2025 Dec;22(6):649-666. Epub 2025 Aug 22. PMID: 40844227; PMCID: PMC12647387.
Placebo rates in randomised clinical trials of ulcerative colitis: An individual patient data meta-analysis
Solitano V, Hogan M, Singh S, et al. J Crohns Colitis. 2025 Nov 8;19(10):jjaf191. PMID: 41206929; PMCID: PMC12668678.
Sodium-glucose co-transporter 2 inhibitors in severe estimated glomerular filtration rate deterioration across cardiovascular-kidney- metabolic conditions: A pooled analysis of randomized trials
Ferreira JP, Marques P, Anker SD, et al. Eur J Heart Fail. 2025 Nov 9. Epub ahead of print. PMID: 41206806.
Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular-kidney-metabolic conditions: A pooled analysis of randomised trials
Ferreira JP, Marques P, Anker SD, et al. Diabetes Obes Metab. 2025 Nov 10. Epub ahead of print. PMID: 41208574.
Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials
Kaster TS, Dai Y, Vila-Rodriguez F, et al. EClinicalMedicine. 2025 Oct 30;90:103609. PMID: 41245530; PMCID: PMC12615302.
Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi-Mechanistic Pharmacometric Framework
Ibrahim EIK, Friberg LE. CPT Pharmacometrics Syst Pharmacol. 2025 Oct 11. Epub ahead of print. PMID: 41074915.
Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data
Jullien A, Jambon-Barbara C, Cracowski JL, et al. Diabetes Care. 2024 Nov 1;47(11):1949-1957. PMID: 39190488.
Predicting Remission in Schizophrenia Using Machine Learning-Assessing the Impact of Sample Size and Predictor Overinclusion
Hieronymus F, Hieronymus M, Sjöstedt A, et al. Acta Psychiatr Scand. 2025 Dec;152(6):441-450. Epub 2025 Sep 10. PMID: 40928163.
Treatment modifiers and predictors of risperidone response in dementia: An individual participant data meta-analysis of six randomized controlled trials
Le HT, Lau ECY, Lu CY, et al. Alzheimers Dement. 2025 Sep;21(9):e70665. PMID: 40916051; PMCID: PMC12414727.
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study
Roy S, Saad F, Malone S, et al. Eur Urol. 2024 Apr;85(4):398-400. PMID: 38485300.
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials
Roy S, Ozay ZI, Guha A, et al. JAMA Netw Open. 2025 Aug 1;8(8):e2527988. PMID: 40833694; PMCID: PMC12368675.
The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials
Shaver AL, Nikita N, Sharma S, et al. Cancers (Basel). 2025 Aug 23;17(17):2747. PMID: 40940844; PMCID: PMC12427571.
Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials
Law-Wan J, Sparfel MA, Derolez S, et al. RMD Open. 2021 Nov;7(3):e001882. PMID: 34789535; PMCID: PMC8601061.
Analyzing Demographic Variabilities Associated With Age of Diagnosis of Schizophrenia Among Patients in Controlled Clinical Trials
Uga A, Singh V, Gopal N, et al. Ann Clin Psychiatry. 2025;36(4):168-175.
Correlations between comorbidities in trials and the community: An individual-level participant data meta-analysis
Crowther J, Butterly EW, Hannigan LJ, et al. J Multimorb Comorb. 2023 Nov 9;13:26335565231213571. PMID: 37953975; PMCID: PMC10637135.
Racial Difference in Efficacy of Golimumab in Ulcerative Colitis
Greywoode R, Petralia F, Ullman TA, et al. Inflamm Bowel Dis. 2023 Jun 1;29(6):843-849. PMID: 35913121; PMCID: PMC10233400.
Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression: a pooled participant analysis of randomized controlled trials
Huc M, Siddiqi S, Myers M, et al. medRxiv. 2025 Jun 28.25330356
Impact of Concomitant Corticosteroid Use on Adverse Events in Ulcerative Colitis Clinical Trials
Hamam H, Dulai PS, Marshall JK, et al. J Crohns Colitis. 2025 Sep 7;19(8):jjaf145. PMID: 40794609; PMCID: PMC12459985.
Comparison of methods that combine multiple randomized trials to estimate heterogeneous treatment effects
Brantner CL, Nguyen TQ, Tang T, et al. Stat Med. 2024 Mar 30;43(7):1291-1314. Epub 2024 Jan 25. PMID: 38273647; PMCID: PMC11086055.
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females
Doi Y, Hamano T, Yamaguchi O, et al. Blood Adv. 2025 Jul 8;9(13):3202-3212. PMID: 40239057; PMCID: PMC12246709.
From trial data to personalized medicine: a validated framework with an application to Crohn’s disease
Rudrapatna VA, Ravindranath VG, Arneson DV, et al. NPJ Digit Med. 2025 May 31;8(1):327. PMID: 40450151; PMCID: PMC12126477.
Placebo Rates in Crohn’s Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis
Solitano V, Hogan M, Singh S, et al. Gastroenterology. 2025 Feb;168(2):344-356. Epub 2024 Oct 15. PMID: 39414161; PMCID: PMC12186694.
Does symptom duration impact on treatment response in axial spondyloarthritis? A meta-analysis of randomized controlled trials
Benavent D, Navarro-Compán V, Capelusnik D, et al. Rheumatology (Oxford). 2025 Nov 1;64(11):5872-5882. PMID: 40644616.
The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
Suartz CV, Roy ML, Toren P. Société Internationale d’Urologie Journal. 2024; 5(4):270-278.
Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn’s Disease: A Post Hoc Analysis of the SEAVUE Trial
Ahuja D, Anvari S, Wong ECL, et al. Inflamm Bowel Dis. 2025 Nov 1;31(11):3103-3111. PMID: 40587369; PMCID: PMC12638049.
The impact of biological interventions on health-related quality of life in adults with Crohn’s disease: a systematic review with meta-analysis
Benić MS, Giljača V, Belančić A, et al. EClinicalMedicine. 2025 Jul 2;85:103320. PMID: 40678697; PMCID: PMC12270664.
FedECA: Federated External Control Arms for Causal Inference with Time-To-Event Data in Distributed Settings
Ogier du Terrail J, Klopfenstein Q, Li H, et al. Nat Commun. 2025 Aug 13;16(1):7496. PMID: 40804048; PMCID: PMC12350967.
Comparative Predictive Utility of MM-SES-CD and SES-CD for Week 52 Endoscopic Remission in the Ileum and Colon in Crohn’s Disease
Wong ECL, Dulai PS, Marshall JK, et al. Inflamm Bowel Dis. 2025 Nov 1;31(11):3044-3050. PMID: 40522972; PMCID: PMC12638060.
Replicating and Extending the Reliability, Criterion Validity, and Treatment Sensitivity of the PANSS10 and PANSS20 for Pediatric Trials
Youngstrom EA, Langfus JA, Daniel DG, et al. JAACAP Open. 2024 May 23;3(2):257-267. PMID: 40520977; PMCID: PMC12166928.
Statin use and survival in SLL/CLL treated with ibrutinib: Pooled analysis of four randomized controlled trials
Abuhelwa AY, Almansour SA, Brown JR, et al. Blood Adv. 2025 Jul 22;9(14):3566-3575. PMID: 40266025; PMCID: PMC12275193.
Three approaches to determining clinically meaningful benefit on the Cohen-Mansfield Agitation Inventory in dementia clinical trials for agitation
Liu KY, Ivenso C, Howard R, et al. Alzheimers Dement (N Y). 2025 May 15;11(2):e70099. PMID: 40376142; PMCID: PMC12079343.
Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events
Wightman H, Butterly E, Wei L, et al. PLoS Med. 2025 Apr 7;22(4):e1004553. PMID: 40193407; PMCID: PMC12052138.
The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophrenia
Nomura N, Siafis S, Schneider-Thoma J, et al. Lancet Psychiatry. 2025 Apr;12(4):266-275. Erratum in: Lancet Psychiatry. 2025 May 8:S2215-0366(25)00159-2. PMID: 40113354.
Estimating target population treatment effects in meta-analysis with individual participant-level data
Hong H, Liu L, Stuart EA. Stat Methods Med Res. 2025 Feb;34(2):355-368. Epub 2025 Jan 19. PMID: 39828917.
Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment: An Individual Participant Data Meta-Analysis
Brandt L, Efthimiou O, Siafis S, et al. JAMA Psychiatry. 2025 Jul 1;82(7):692-700. PMID: 40332874; PMCID: PMC12060018.
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma
Abuhelwa AY, Almansour SA, Basch E, et al. Eur J Haematol. 2025 Jun;114(6):1020-1031. Epub 2025 Mar 14. PMID: 40084510; PMCID: PMC12053969.
Extension and Further Replication of the Reliability, Criterion Validity, and Treatment Sensitivity of the PANSS10 and PANSS20 for Pediatric Trials
Langfus JA, Youngstrom EA, Daniel D, et al. J Child Adolesc Psychopharmacol. 2024 Dec;34(10):447-457. Epub 2024 Oct 17. PMID: 39419042; PMCID: PMC11807860.
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
Razaghizad A, Ni J, Marques P, et al. Diabetes Obes Metab. 2024 Nov;26(11):5025-5035. Epub 2024 Sep 20. PMID: 39301712.
Predicting failure of methotrexate therapy in patients with rheumatoid arthritis: statistical approaches to multiple outcomes and alternative therapies
Gehringer, C. PhD thesis. 2024: The University of Manchester.
Serum Albumin and Its Trajectory Are Associated With Therapeutic Outcomes in Ulcerative Colitis
Zheng J, Zhang X, Zhang L, et al. Clin Gastroenterol Hepatol. 2025 Sep;23(10):1808-1816. Epub 2024 Dec 16. PMID: 39694206.
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis
Hanlon P, Butterly E, Wei L, et al. JAMA. 2025 Mar 25;333(12):1062-1073. PMID: 39899304; PMCID: PMC11791772.
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer
Fukuokaya W, Mori K, Yanagisawa T, et al. Cancer. 2025 Apr 1;131(7):e35819. PMID: 40106307; PMCID: PMC11922167.
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial
Roy S, Saad F, Sun Y, et al. Eur J Cancer. 2024 Nov;211:114197. Epub 2024 Jun 27. PMID: 39243730.
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial
Roy S, Malone S, Wing K, et al. JAMA Netw Open. 2024 Oct 1;7(10):e2439434. PMID: 39405060; PMCID: PMC11581638.
Sequential regression and simulation: a method for estimating causal effects from heterogeneous clinical trials without a common control group
Rudrapatna VA, Ravindranath VG, Arneson DV, et al. BMC Med Res Methodol. 2023 Oct 3;23(1):218. PMID: 37789257; PMCID: PMC10546672.
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis
Khan FA, Stewart I, Saini G, et al. Eur Respir J. 2021 Sep 29;59(4):2101612. PMID: 34588192; PMCID: PMC9202487.
Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis
Solitano V, Panaccione R, Sands BE, et al. Med. 2025 Feb 14;6(2):100512. Epub 2024 Oct 4. PMID: 39368474; PMCID: PMC12239942.
Outcomes of patients with prior biologic intolerance are better than those with biologic failure in clinical trials of inflammatory bowel disease
Samnani S, Wong ECL, Hamam H, et al. J Crohns Colitis. 2025 Mar 5;19(3):jjae151. PMID: 39302135; PMCID: PMC11945295.
No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis
Ahuja D, Zou G, Solitano V, et al. Clin Gastroenterol Hepatol. 2025 Sep;23(10):1786-1797. Epub 2024 Oct 11. PMID: 39395572; PMCID: PMC12186698.
Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations
Rippin G, Sanz H, Hoogendoorn WE, et al. Drug Saf. 2024 Dec;47(12):1245-1263. Epub 2024 Aug 5. PMID: 39102176; PMCID: PMC11554740.
Pooling Alzheimer’s disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof-of-principle study and call to action
Dubbelman MA, Vromen EM, Tijms BM, et al. Alzheimers Dement (N Y). 2024 Aug 7;10(3):e12485. PMID: 39114370; PMCID: PMC11303826.
Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications
Kerr WT, Kok N, Reddy AS, et al. Neurology. 2024 Aug 27;103(4):e209713. Epub 2024 Jul 25. PMID: 39052963; PMCID: PMC11271390.
Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data
Hanlon P, Butterly E, Shah ASV, et al. BMC Med. 2022 Oct 28;20(1):410. PMID: 36303169; PMCID: PMC9615407.
Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn’s Disease: A Post Hoc Analysis of the REACH Trial
Cheifetz AS, Vande Casteele N, Wang Z, et al. Am J Gastroenterol. 2023 Mar 1;118(3):485-490. Epub 2022 Dec 23. PMID: 36624036; PMCID: PMC9991960.
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers
Bayani DB, Lin YC, Nagarajan C, et al. Pharmacoecon Open. 2024 Sep;8(5):651-664. Epub 2024 Jun 20. PMID: 38900407; PMCID: PMC11362436.
Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials
Vuyyuru SK, Ma C, Nguyen TM, et al. EClinicalMedicine. 2024 May 4;72:102621. PMID: 38726222; PMCID: PMC11079462.
Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer’s Disease Clinical Trials
Wang D, Ling Y, Harris K, et al. medRxiv [Preprint]. 2023 Oct 30:2023.10.27.23297685. PMID: 37961216; PMCID: PMC10635230.
Personalizing treatment selection in Crohn’s disease: a meta-analysis of individual participant data from fifteen randomized controlled trials
Rudrapatna VA, Ravindranath VG, Arneson DV, et al. medRxiv [Preprint]. 2023 Nov 12:2023.11.10.23291837. PMID: 37986977; PMCID: PMC10659518.
Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity
Guo X, Bourgeois FT, Cai T. Stat Methods Med Res. 2024 Jul;33(7):1152-1162. Epub 2024 May 8. PMID: 38717356.
Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn’s Disease
Narula N, Wong ECL, Aruljothy A, et al. J Clin Gastroenterol. 2023 Oct 1;57(9):913-919. PMID: 36227009.
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease
Wong ECL, Dulai PS, Marshall JK, et al. Inflamm Bowel Dis. 2023 Sep 1;29(9):1390-1398. PMID: 36426810.
Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis
Pray C, Wong ECL, Aruljothy A, et al. Inflamm Bowel Dis. 2023 Aug 1;29(8):1263-1271. PMID: 36179118.
Calibrated meta-analysis to estimate the efficacy of mental health treatments in target populations: an application to paliperidone trials for treatment of schizophrenia
Hong H, Liu L, Mojtabai R, et al. BMC Med Res Methodol. 2023 Jun 26;23(1):150. PMID: 37365521; PMCID: PMC10294408.
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study
Dennis JM, Young KG, McGovern AP, et al. Lancet Digit Health. 2022 Dec;4(12):e873-e883. PMID: 36427949.
Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer
Ni X, Wu J, Pan J, et al. Eur Urol Oncol. 2024 Aug;7(4):897-905. Epub 2023 Dec 26. PMID: 38151441.
Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysis
Butterly EW, Hanlon P, Shah ASV, et al. PLoS Med. 2023 Jan 17;20(1):e1004154. PMID: 36649256; PMCID: PMC9844862.
Effect of age, sex, and morbidity count on trial attrition: meta-analysis of individual participant level data from phase 3/4 industry funded clinical trials
Lees JS, Hanlon P, Butterly EW, et al. BMJ Med. 2022 Sep 1;1(1):e000217. PMID: 36936559; PMCID: PMC9978693.
Frailty in randomised controlled trials for dementia or mild cognitive impairment measured via the frailty index: prevalence and prediction of serious adverse events and attrition
Wightman H, Quinn TJ, Mair FS, et al. Alzheimers Res Ther. 2023 Jun 13;15(1):110. PMID: 37312157; PMCID: PMC10262528.
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial
Roy S, Sun Y, Chi KN, et al. J Urol. 2024 Nov;212(5):672-681. Epub 2024 Jul 26. PMID: 39058790.
Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials
Almansour SA, Alqudah MAY, Abuhelwa Z, et al. Ther Adv Med Oncol. 2024 Sep 2;16:17588359241275387. PMID: 39229471; PMCID: PMC11369879.
Sequential covariate-adjusted randomization via hierarchically minimizing Mahalanobis distance and marginal imbalance
Yang H, Qin Y, Li Y, et al. Biometrics. 2024 Mar 27;80(2):ujae047. PMID: 38801258.
Balancing covariates in multi-arm trials via adaptive randomization
Yang H, Qin Y, Wang F, et al. Comput Stat Data Anal. 2023 March; 179:107642.
Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate
Fukuokaya W, Mori K, Urabe F, et al. JAMA Netw Open. 2024 Mar 4;7(3):e242467. PMID: 38488793; PMCID: PMC10943414.
Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study
Roy S, Saad F, Wallis CJD, et al. Eur J Cancer. 2024 Mar;199:113348. Epub 2023 Sep 20. PMID: 38262848.
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis
Siafis S, Brandt L, McCutcheon RA, et al. Lancet Psychiatry. 2024 Jan;11(1):36-46. Epub 2023 Nov 30. PMID: 38043562.
Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer
Roy S, Wallis CJD, Morgan SC, et al. Prostate. 2023 Jul;83(10):912-921. Epub 2023 Apr 18. PMID: 37071764.
Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trials
Hanlon P, Butterly EW, Shah AS, et al. PLoS Med. 2023 Jun 6;20(6):e1004176. PMID: 37279199; PMCID: PMC10243630.
Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer
Roy S, Sun Y, Wallis CJD, et al Prostate Cancer Prostatic Dis. 2023 Mar;26(1):119-125. Epub 2022 Jul 5. PMID: 35790787.
Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial
Fukuokaya W, Yanagisawa T, Mori K, et al. Eur Urol Oncol. 2025 Apr;8(2):263-269. Epub 2024 Apr 30. PMID: 38688767.
Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in clinical trials of ulcerative colitis
Narula N, Hamam H, Liu J, et al. J Crohns Colitis. 2024 Nov 4;18(11):1863-1869. PMID: 38869911; PMCID: PMC11532608.
Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis
Zheng J, Wang Y, Li L, et al. Int Immunopharmacol. 2024 Aug 20;137:112506. Epub 2024 Jun 23. PMID: 38914032.
Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis
Bilal A, Yi F, Gonzalez GR, et al. J Diabetes Complications. 2024 Aug;38(8):108783. Epub 2024 Jun 8. PMID: 38870731.
Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse
McCutcheon RA, Taylor D, Rubio J, et al. Schizophr Bull. 2024 Apr 30;50(3):513-520. PMID: 37797288; PMCID: PMC11059789.
The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials
Takase-Minegishi K, Böhringer S, Nam JL, et al. Rheumatology (Oxford). 2025 Feb 1;64(2):548-560. PMID: 38366945.
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
Khan MS, Segar MW, Usman MS, et al. JACC Heart Fail. 2023 Jul;11(7):825-835. Epub 2023 May 24. PMID: 37227388.
Bedaquiline exposure in people with drug-resistant TB treatedfor diabetes: analysis of two phase 2 trials
Bolhuis MS, Akkerman OW, Sturkenboom MGG, et al. Int J Tuberc Lung Dis. 2023 Apr 1;27(4):335-337. PMID: 37035978.
Identifying surrogate markers in real-world comparativeeffectiveness research
Han L, Wang X, Cai T. Stat Med. 2022 Nov 20;41(26):5290-5304. Epub 2022 Sep 5. PMID: 36062392.
Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial
Fukuokaya W, Yanagisawa T, Mori K, et al. Eur Urol Oncol. 2025 Apr;8(2):263-269. Epub 2024 Apr 30. PMID: 38688767.
Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer
Ni X, Luu M, Ma W, et al. J Natl Compr Canc Netw. 2023 Jul;21(7):733-741.e3. PMID: 37433430.
Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages
Hopkins AM, Modi ND, Abuhelwa AY, et al. JAMA Oncol. 2023 Dec 1;9(12):1621-1626. PMID: 37796495; PMCID: PMC10557028.
Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials
Almansour SA, Alqudah MAY, Abuhelwa Z, et al. Sci Rep. 2024 Jan 5;14(1):591. PMID: 38182614; PMCID: PMC10770405.
Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes
Chen R, Tie Y, Huang Y, et al. United European Gastroenterol J. 2024 May;12(4):459-468. Epub 2023 Dec 30. PMID: 38159047; PMCID: PMC11091780.
Illusory generalizability of clinical prediction models
Chekroud AM, Hawrilenko M, Loho H, et al. Science. 2024 Jan 12;383(6679):164-167. Epub 2024 Jan 11. PMID: 38207039.
Combining Real-World and Randomized Control Trial Data Using Data-Adaptive Weighting via the On-Trial Score
Harton J, Segal B, Mamtani R, et al. Stat Biopharm Res. 2022;15(2):408–20.
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials
Fukuokaya W, Mori K, Yanagisawa T, et al. Prostate Cancer Prostatic Dis. 2024 Sep;27(3):444-450. Epub 2023 Jul 18. PMID: 37464102.
A powerful partnership: researchers and patients working together to develop a patient-facing summary of clinical trial outcome data
Ruzich E, Ritchie J, Ginchereau Sowell F, et al. J Am Med Inform Assoc. 2024 Jan 18;31(2):363-374. PMID: 37341698; PMCID: PMC10797263.
Linkage of Young Mania Rating Scale to Clinical Global Impression Scale to Enhance Utility in Clinical Practice and Research Trials
Samara MT, Levine SZ, Leucht S. Pharmacopsychiatry. 2023 Jan;56(1):18-24. Epub 2022 Jul 27. PMID: 35896419.
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Nikolin S, Rodgers A, Schwaab A, et al. EClinicalMedicine. 2023 Aug 3;62:102127. PMID: 37593223; PMCID: PMC10430179.
Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis
Chen R, Li L, Tie Y, et al. Precis Clin Med. 2023 Sep 5;6(3):pbad022. PMID: 38025971; PMCID: PMC10680133.
Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer
Roy S, Sun Y, Wallis CJD, et al. Cancers (Basel). 2023 Sep 2;15(17):4392. PMID: 37686668; PMCID: PMC10486494.
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis
Bittner N, Funk CSM, Schmidt A, et al. Drugs Aging. 2023 Nov;40(11):953-964. Epub 2023 Sep 8. PMID: 37682445; PMCID: PMC10600312.
Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
Mathai DS, Nayak SM, Yaden DB, et al. Psychopharmacology (Berl). 2023 Apr;240(4):827-836. Epub 2023 Feb 2. PMID: 36729145.
Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index
Wong ECL, Dulai PS, Marshall JK, et al. Inflamm Bowel Dis. 2024 Mar 1;30(3):370-381. PMID: 37116893.
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders
Wong ECL, Dulai PS, Marshall JK, et al. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3387-3396.e1. Epub 2023 Jun 29. PMID: 37391059.
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial
Doi Y, Hamano T, Yamaguchi S, et al. Diabetes Obes Metab. 2023 Oct;25(10):2944-2953. Epub 2023 Jun 29. PMID: 37385955.
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes
Oikonomou EK, Suchard MA, McGuire DK, et al. Diabetes Care. 2022 Apr 1;45(4):965-974. PMID: 35120199; PMCID: PMC9016734.
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease
d’Angremont E, Begemann MJH, van Laar T, et al. JAMA Neurol. 2023 Aug 1;80(8):813-823. PMID: 37358841; PMCID: PMC10294019.
Fecal lactoferrin early predicts long-term outcomes in ulcerative colitis: A post-hoc analysis of the UNIFI and PURSUIT trials
Chen R, Tie Y, Zhang X, et al. United European Gastroenterol J. 2023 Jul;11(6):542-550. Epub 2023 Jun 23. PMID: 37350349; PMCID: PMC10337733.
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis
Hock RS, Feeney A, Iovieno N, et al. J Clin Psychiatry. 2022 Dec 12;84(1):21r14086. PMID: 36516320.
Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients with Diabetes Mellitus: New Insights from CANVAS
Borisov AN, Kutz A, Christ ER, et al. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2940-2949. PMID: 37149821; PMCID: PMC10584001.
Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study
Wong ECL, Merat S, Monaco C, et al. Dig Dis Sci. 2023 Jun;68(6):2635-2646. Epub 2023 Apr 29. PMID: 37119375.
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Halabi S, Yang Q, Roy A, et al. J Clin Oncol. 2023 May 20;41(15):2736-2746. Epub 2023 Apr 11. PMID: 37040594; PMCID: PMC10414709.
Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials
Burschinski A, Schneider-Thoma J, Chiocchia V, et al. World Psychiatry. 2023 Feb;22(1):116-128. PMID: 36640396; PMCID: PMC9840505.
Guiding safer risperidone prescribing in Alzheimer’s disease with therapeutic drug monitoring
Roughley M, Mena C, Howard R, et al. Br J Clin Pharmacol. 2023 Jul;89(7):2316-2321. Epub 2023 Feb 28. PMID: 36791792.
External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning
Loiseau N, Trichelair P, He M, et al. BMC Med Res Methodol. 2022 Dec 28;22(1):335. PMID: 36577946; PMCID: PMC9795588.
Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis
Veroniki AA, Ashoor HM, Rios P, et al. BMJ Open. 2022 Apr 26;12(4):e053012. PMID: 35473731; PMCID: PMC9045061.
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS
Hopkins SC, Ogirala A, Zeni C, et al. Clin Drug Investig. 2022 Dec;42(12):1113-1121. Epub 2022 Nov 9. PMID: 36350559; PMCID: PMC9705451.
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial
Roy S, Sun Y, Morgan SC, et al. Eur Urol. 2023 Jun;83(6):571-579. Epub 2023 Mar 7. PMID: 36894488.
Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis
Brandt L, Ritter K, Schneider-Thoma J, et al. Lancet Psychiatry. 2023 Mar;10(3):184-196. PMID: 36804071.
Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports
Siebert M, Gaba J, Renault A, et al. BMC Med. 2022 May 20;20(1):177. PMID: 35590360; PMCID: PMC9119701.
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis
Papamichael K, Vande Casteele N, Jeyarajah J, et al. Am J Gastroenterol. 2021 May 1;116(5):1007-1014. PMID: 33929379; PMCID: PMC8095681.
A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn’s Disease
Dulai PS, Jairath V, Narula N, et al. Am J Gastroenterol. 2021 Aug 1;116(8):1709-1719. PMID: 34587127; PMCID: PMC8481677.
Vibration of effect in more than 16,000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis
Gouraud H, Wallach JD, Boussageon R, et al. BMJ Med. 2022 Sep 14;1(1):e000154. PMID: 36936564; PMCID: PMC9978683.
Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis
McCutcheon RA, Pillinger T, Efthimiou O, et al. World Psychiatry. 2022 Jun;21(2):287-294. PMID: 35524614; PMCID: PMC9077611.
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis
Wong ECL, Dulai PS, Marshall JK, et al. Clin Gastroenterol Hepatol. 2023 Apr;21(4):1050-1060.e9. Epub 2022 Aug 25. PMID: 36029969.
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis
Kerschbaumer A, Rivai ZI, Smolen JS, et al. Ann Rheum Dis. 2022 Oct;81(10):1374-1378. Epub 2022 Jun 20. PMID: 35725294.
The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data
Zou X, Huang Q, Luo Y, et al. Diabetologia. 2022 Sep;65(9):1424-1435. Epub 2022 Jul 8. PMID: 35802168.
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease
Narula N, Wong ECL, Dulai PS, et al. Am J Gastroenterol. 2022 Jul 1;117(7):1106-1117. Epub 2022 Apr 15. PMID: 35435862.
Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials
Agrawal M, Petralia F, Tepler A, et al. Inflamm Bowel Dis. 2023 Jan 5;29(1):1-8. PMID: 35366313; PMCID: PMC10091488.
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
Mishriky BM, Cummings DM, Powell JR. Prim Care Diabetes. 2022 Jun;16(3):471-473. Epub 2022 Apr 5. PMID: 35396200.
Three-Month FVC Change: A Trial Endpoint for IPF Based on Individual Participant Data Meta-Analysis
Khan FA, Stewart I, Moss S, et al. Am J Respir Crit Care Med. 2022 Apr 15;205(8):936-948. PMID: 35020580.
Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study
Kearns B, Stevenson MD, Triantafyllopoulos K, et al. BMC Med Res Methodol. 2021 Nov 27;21(1):263. PMID: 34837957; PMCID: PMC8627632.
Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn’s Disease
Narula N, Wong ECL, Colombel JF, et al. J Crohns Colitis. 2022 May 10;16(4):616-624. PMID: 34664635; PMCID: PMC9274823.
Categorizing Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD (MM-SES-CD)
Narula N, Pray C, Wong ECL, et al. J Crohns Colitis. 2022 Aug 4;16(7):1011-1019. PMID: 35134140.
Explainable AI enables clinical trial patient selection to retrospectively improve treatment effects in schizophrenia
Mellem MS, Kollada M, Tiller J, et al. BMC Med Inform Decis Mak. 2021 May 20;21(1):162. PMID: 34016112; PMCID: PMC8135147.
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials
Carretero-González A, Lora D, Manneh R, et al. Clin Transl Oncol. 2020 Nov;22(11):2126-2129. Epub 2020 Mar 20. PMID: 32198642.
Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis
Wang R, Dasgupta A, Ward MM. JAMA Netw Open. 2022 Mar 1;5(3):e222312. PMID: 35289857; PMCID: PMC8924712.
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
Wang J, Arroyo-Suarez R, Dasari S, et al. Leuk Lymphoma. 2022 Jul;63(7):1669-1677. Epub 2022 Feb 10. PMID: 35142582.
Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease
Wong ECL, Dulai PS, Marshall JK, et al. Aliment Pharmacol Ther. 2022 May;55(9):1151-1159. Epub 2022 Feb 15. PMID: 35166396.
Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis
Brandt L, Schneider-Thoma J, Siafis S, et al. Lancet Psychiatry. 2022 Mar;9(3):232-242. PMID: 35183280.
Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials
Sim R, Chong CW, Loganadan NK, et al. Diabet Med. 2022 Mar;39(3):e14780. Epub 2022 Jan 5. PMID: 34962662.
Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn’s Disease: A Pooled Analysis of 6 Trials
Beelen EMJ, Nieboer D, Arkenbosch JHC, et al. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2741-2752.e6. Epub 2021 Oct 20. PMID: 34687970.
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials
Ben-Horin S, Novack L, Mao R, et al. Gastroenterology. 2022 Feb;162(2):482-494. Epub 2021 Oct 29. PMID: 34757139.
Meta-analysis of Total Effect Decomposition in the Presence of Multiple Mediators: The Example of Schizophrenia Treatment
Zhu Y, Centorrino F, Jackson JW, et al. Epidemiology. 2021 Jan;32(1):120-130. PMID: 33181564.
Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis
Narula N, Wong ECL, Marshall JK, et al. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1588-1597.e3. Epub 2021 Jul 28. PMID: 34329776.
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer
Lorente D, Llacer C, Lozano R, et al. Eur Urol. 2021 Nov;80(5):641-649. Epub 2021 Aug 6. PMID: 34373138.
Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data
Schoretsanitis G, Kane JM, Correll CU, et al. Schizophr Bull. 2022 Mar 1;48(2):296-306. PMID: 34355232; PMCID: PMC8886604.
Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
Hieronymus F, Kølbæk P, Correll CU, et al. NPJ Schizophr. 2021 Aug 27;7(1):41. PMID: 34453057; PMCID: PMC8397783.
Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports
Hodkinson A, Heneghan C, Mahtani KR, et al. BMC Med. 2021 Aug 25;19(1):195. PMID: 34429113; PMCID: PMC8386072.
Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials
Pan J, Wang J, Wei Y, et al. Cancer Med. 2021 Oct;10(19):6697-6704. Epub 2021 Aug 20. PMID: 34414685; PMCID: PMC8495267.
The impact of ustekinumab on extraintestinal manifestations of Crohn’s disease: A post hoc analysis of the UNITI studies
Narula N, Aruljothy A, Wong ECL, et al. United European Gastroenterol J. 2021 Jun;9(5):581-589. Epub 2021 Jun 2. PMID: 34077627; PMCID: PMC8259251.
Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis
Wang L, Paller C, Hong H, et al. J Natl Cancer Inst. 2022 Feb 7;114(2):191-202. PMID: 33830214; PMCID: PMC8826526.
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis
Ternov KK, Nolsøe AB, Bratt O, et al. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):948-961. Epub 2021 Apr 5. PMID: 33820951.
Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials
Wang J, Park C, Arroyo-Suarez R. Leuk Lymphoma. 2021 Sep;62(9):2219-2226. Epub 2021 Apr 9. PMID: 33836624.
Comparative Efficacy and Rapidity of Action for Infliximab vs. Ustekinumab in Biologic Naive Crohn’s Disease
Narula N, Wong ECL, Dulai PS, et al. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1579-1587.e2. Epub 2021 Apr 7. PMID: 33838348.
Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD)
Narula N, Wong ECL, Colombel JF, et al. Gut. 2022 Jun;71(6):1078-1087. Epub 2021 Mar 25. PMID: 33766910.
Outcomes of Passable and Non-Passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis
Narula N, Wong ECL, Dulai PS, et al. J Crohns Colitis. 2021 Oct 7;15(10):1649-1657. PMID: 33693522.
OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies
Fraenkel L, Wei Z, Ramsey C, et al. PLoS One. 2021 Jan 29;16(1):e0245598. Erratum in: PLoS One. 2021 Mar 9;16(3):e0248598. PMID: 33513209; PMCID: PMC7846019.
Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis
Mishriky BM, Okunrintemi V, Jain S, et al. Diabetes Metab. 2021 Feb;47(1):101160. Epub 2020 May 18. PMID: 32439471.
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease
Papamichael K, Vande Casteele N, Jeyarajah J, et al. Am J Gastroenterol. 2021 May 1;116(5):1007-1014. PMID: 33929379; PMCID: PMC8095681.
No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis
Marques ML, Ramiro S, Machado PM, et al. RMD Open. 2020 Dec;6(3):e001391. PMID: 33310864; PMCID: PMC7856152.
The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies
Lu TX, Dapas M, Lin E, et al. Gut. 2021 Nov;70(11):2076-2084. Epub 2020 Dec 17. PMID: 33334900.
Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP)
Rabinowitz J, Opler M, Rabinowitz AA, et al. Schizophr Res. 2021 Feb;228:529-533. Epub 2020 Nov 25. PMID: 33248884.
Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial
Wong ECL, Marshall JK, Reinisch W, et al. Inflamm Bowel Dis. 2021 May 17;27(6):848-854. PMID: 32812022.
Identifying frailty in trials: an analysis of individual participant data from trials of novel pharmacological interventions
Hanlon P, Butterly E, Lewsey J, et al. BMC Med. 2020 Oct 22;18(1):309. PMID: 33087107; PMCID: PMC7579922.
Week 6 Calprotectin Best Predicts Likelihood of Long-Term Endoscopic Healing in Crohn’s Disease: A Post-Hoc Analysis of the UNITI/IM-UNITI Trials
Narula N, Wong ECL, Dulai PS, et al. J Crohns Colitis. 2021 Mar 5;15(3):462-470. PMID: 32931556.
Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients
Ferreira RJO, Welsing PMJ, Jacobs JWG, et al. Ann Rheum Dis. 2021 Mar;80(3):293-303. Epub 2020 Oct 6. PMID: 33023964.
Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis
Rubio JM, Schoretsanitis G, John M, et al. Lancet Psychiatry. 2020 Sep;7(9):749-761. PMID: 32828165.
Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial
Narula N, Wong ECL, Aruljothy A, et al. Am J Gastroenterol. 2020 Aug;115(8):1236-1245. PMID: 32759621.
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn’s Disease: A Systematic Review and Pooled Meta-analysis
Faleck DM, Shmidt E, Huang R, et al. Clin Gastroenterol Hepatol. 2021 Feb;19(2):238-245.e4. Epub 2020 Jun 20. PMID: 32569749; PMCID: PMC8364422.
Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis
Hanlon P, Hannigan L, Rodriguez-Perez J, et al. BMC Med. 2019 Nov 12;17(1):201. PMID: 31711480; PMCID: PMC6849229.
Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials
Cheng D, Cushing KC, Cai T, et al. Clin Gastroenterol Hepatol. 2021 May;19(5):939-946.e4. Epub 2020 May 1. PMID: 32371165.
Bayesian Meta-Analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs
Spertus J, Horvitz-Lennon M, Normand ST. Med Decis Making. 2019 Jul;39(5):583-592. Epub 2019 Aug 2. PMID: 31375050; PMCID: PMC6786940.
Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials
Christian KE, Russman KM, Rajan DP, et al. Inflamm Bowel Dis. 2020 Jan 1;26(1):125-131. PMID: 31265730.
Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis
Schneider-Thoma J, Efthimiou O, Bighelli I, et al. Lancet Psychiatry. 2019 Sep;6(9):753-765. Epub 2019 Jul 15. PMID: 31320283.
Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis
Singh S, Proudfoot JA, Dulai PS, et al. Clin Gastroenterol Hepatol. 2020 Feb;18(2):424-431.e7. Epub 2019 May 18. PMID: 31108227; PMCID: PMC6858937.
Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease
Waljee AK, Wallace BI, Cohen-Mekelburg S, et al. JAMA Netw Open. 2019 May 3;2(5):e193721. Erratum in: JAMA Netw Open. 2019 Jun 5;2(6):e197386. PMID: 31074823; PMCID: PMC6512283.
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302
Teply BA, Qiu F, Antonarakis ES, et al. Prostate. 2019 Jun;79(8):929-933. PMID: 31059588.
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
Mbuagbaw L, Guglielmetti L, Hewison C, et al. Emerg Infect Dis. 2019 May;25(5):936-943. PMID: 31002070; PMCID: PMC6478224.
External Validation of a Thiopurine Monitoring Algorithm on the SONIC Clinical Trial Dataset
Waljee AK, Sauder K, Zhang Y, et al. Clin Gastroenterol Hepatol. 2018 Mar;16(3):449-451. Epub 2017 Aug 22. PMID: 28838785; PMCID: PMC5816686.
A Standardisation Approach to Compare Treatment Safety and Effectiveness Outcomes between Clinical Trials and Real World Populations in Psoriasis
Yiu ZZN, Mason KJ, Barker JNWN, et al. Br J Dermatol. 2019 Dec;181(6):1265-1271. Epub 2019 Jul 2. PMID: 30822358; PMCID: PMC6916305.
Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study
Loubersac T, Nguile-Makao M, Pouliot F, et al. Eur Urol Oncol. 2020 Jun;3(3):298-305. Epub 2019 Jan 31. PMID: 31411963.
Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low vs. high risk of radiographic progression: An analysis of COU-AA-302
Martin LJ, Alibhai SMH, Komisarenko M, et al. Can Urol Assoc J. 2019 Jun;13(6):192-200. PMID: 30407155; PMCID: PMC6570594.
Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs
Kumagai F, Suzuki T, Fleischhacker WW, et al. J Clin Psychiatry. 2018 Dec 4;80(1):18m12144. PMID: 30549487.
Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs
Kubo K, Fleischhacker WW, Suzuki T, et al. Acta Psychiatr Scand. 2019 Feb;139(2):108-116. Epub 2018 Sep 9. PMID: 30198163.
Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: a Systematic Review and Meta-Analysis
Narula N, Alshahrani AA, Yuan Y, et al. Clin Gastroenterol Hepatol. 2019 Feb;17(3):411-418.e3. Epub 2018 Jun 18. PMID: 29913273.
Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials
Schneider-Thoma J, Efthimiou O, Huhn M, et al. Lancet Psychiatry. 2018 Aug;5(8):653-663. Epub 2018 Jul 2. PMID: 30042077.
The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data
Wilcox MA, Savitz AJ, Addington AM, et al. NPJ Schizophr. 2018 Jun 27;4(1):14. PMID: 29950580; PMCID: PMC6021398.
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus J, Horvitz-Lennon M, Abing H, et al. NPJ Schizophr. 2018 Jun 27;4(1):12. PMID: 29950586; PMCID: PMC6021430.
The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: a causal mediation analysis approach
Zou X, Zhu Y, Jackson JW, et al. NPJ Schizophr. 2018 Jun 27;4(1):13. PMID: 29950691; PMCID: PMC6021395.
Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials
Singh S, Proudfoot J, Xu R, et al. Inflamm Bowel Dis. 2018 Sep 15;24(10):2278-2284. Erratum in: Inflamm Bowel Dis. 2019 Sep 18;25(10):e134. PMID: 29788260; PMCID: PMC6140448.
Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials
Singh S, Proudfoot J, Xu R, et al. Am J Gastroenterol. 2018 Jun;113(6):883-889. Epub 2018 Jun 5. Erratum in: Am J Gastroenterol. 2019 Jun;114(6):1011. PMID: 29867171; PMCID: PMC7107273.
No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials
Singh S, Proudfoot JA, Dulai PS, et al. Am J Gastroenterol. 2018 Aug;113(8):1197-1205. Epub 2018 Jun 21. Erratum in: Am J Gastroenterol. 2019 Jun;114(6):1010. PMID: 29925913; PMCID: PMC7107271.
Review of Available Evidence on the Use of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis: Data Analysis Report
Mbuagbaw L. Geneva; 2017. WHO reference number: WHO/HTM/TB/2017.01
Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis
Wang R, Dasgupta A, Ward MM. J Rheumatol. 2018 Apr;45(4):481-490. Epub 2018 Jan 15. PMID: 29335342; PMCID: PMC11034828.
Feasibility, Process, and Outcomes of Cardiovascular Clinical Trial Data Sharing: A Reproduction Analysis of the SMART-AF Trial
Gay HC, Baldridge AS, Huffman MD. JAMA Cardiol. 2017 Dec 1;2(12):1375-1379. PMID: 29049540; PMCID: PMC5814997.
Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis Following Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Systematic Review and Economic Evaluation
Corbett M, Chehadah F, Biswas M, et al. Health Technol Assess. 2017 Oct;21(56):1-326. PMID: 28976302; PMCID: PMC5641819.
Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Spine Fusion: A Systematic Review and Meta-analysis
Fu R, Selph S, McDonagh M, et al. Ann Intern Med. 2013 Jun 18;158(12):890-902. PMID: 23778906.
5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI)
Mospan GA, Wargo KA. J Am Board Fam Med. 2016 Nov 12;29(6):654-662. PMID: 28076247.
Meta-Analysis of the Impact of Patient Characteristics on Estimates of Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Lumbar Spinal Fusion
Laurie AL, Chen Y, Chou R, et al. Spine (Phila Pa 1976). 2016 Sep 15;41(18):E1115-E1123. PMID: 27031772.
What Is the Clinical Relevance of Radiographic Nonunion After Single-Level Lumbar Interbody Arthrodesis in Degenerative Disc Disease?: A Meta-Analysis of the YODA Project Database
Noshchenko A, Lindley EM, Burger EL, et al. Spine (Phila Pa 1976). 2016 Jan;41(1):9-17. PMID: 26274529.
Safety and Effectiveness of Recombinant Human Bone Morphogenetic Protein-2 for Spinal Fusion: A Meta-analysis of Individual-Participant Data
Simmonds MC, Brown JV, Heirs MK, et al. Ann Intern Med. 2013 Jun 18;158(12):877-89. PMID: 23778905.
Comparative safety and effectiveness of cognitive enhancers for Alzheimer’s dementia: protocol for a systematic review and individual patient data network meta-analysis
Veroniki AA, Ashoor HM, Rios P, et al. BMJ Open. 2022 Apr 26;12(4):e053012. PMID: 35473731; PMCID: PMC9045061.